Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection.
10.19540/j.cnki.cjcmm.20200828.601
- Author:
Yuan-Min YANG
1
;
Li-Na CHEN
1
;
Shui-Qing QU
2
;
Shuo-Qiu DENG
1
;
Hui LIU
2
;
Xi WANG
3
;
Xiao-Gang WENG
4
;
Ya-Jie WANG
4
;
Xiao-Xin ZHU
4
;
Yu-Jie LI
1
Author Information
1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Artemisinin Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China.
3. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Pharmacy, Shanxi Medical University Taiyuan 030001, China.
4. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
2019-nCoV;
COVID-19;
artemisinin;
artemisinin derivatives;
cardiovascular disease;
drug repurposing;
heart injury
- MeSH:
Artemisinins;
COVID-19;
Cardiovascular Diseases;
Heart Diseases;
Humans;
SARS-CoV-2
- From:
China Journal of Chinese Materia Medica
2020;45(24):6053-6064
- CountryChina
- Language:Chinese
-
Abstract:
Corona virus disease 2019(COVID-19) has brought untold human sufferings and economic tragedy worldwide. It causes acute myocardial injury and chronic damage of cardiovascular system, which has attracted much attention from researchers. For the immediate strategy for COVID-19, "drug repurposing" is a new opportunity for developing drugs to fight COVID-19. Artemisinin and its derivatives have a wide range of pharmacological activities. Recent studies have shown that artemisinin has clear cardiovascular protective effects. This paper summarizes the research progress on the pathogenesis the pathogenesis of COVID-19 in cardiovascular damage by 2019 novel coronavirus(2019-nCoV) virus from myocardial cell injury directly by 2019-nCoV virus,viral ligands competitively bind to ACE2 and then reduce the protective effect of ACE2 on cardiovascular disease, "cytokine storm" related myocardial damage, arrhythmia and sudden cardiac death induced by the infection and stress, myocardial injury by hypoxemia, heart damage side effects from COVID-19 drugs and summarizing the cardiovascular protective effects of artemisinin and its derivatives have activities of anti-arrhythmia, anti-myocardial ischemia, anti-atherosclerosis and plaque stabilization. Then analyzed the possible multi-pathway intervention effects of artemisinin-based drugs on multiple complications of COVID-19 based on its specific immunomodulatory effects, protective effects of tissue and organ damage and broad-spectrum antiviral effect, to provide clues for the treatment of cardiovascular complications of COVID-19, and give a new basis for the therapy of COVID-19 through "drug repurposing".
